Evidence map›Paper›PMID 31243222›Full record

Trial reportInternal medicine (Tokyo, Japan)2019

Changes in the Serum Hepcidin-to-ferritin Ratio with Erythroferrone after Hepatitis C Virus Eradication Using Direct-acting Antiviral Agents.

Shinjiro Inomata, Akira Anan, Eri Yamauchi, Ryo Yamauchi, Hideo Kunimoto, Kazuhide Takata, Takashi Tanaka, Keiji Yokoyama, Daisuke Morihara, Yasuaki Takeyama and 4 more

Abstract readClinical Trial
In one paragraph

Trial report in Internal medicine (Tokyo, Japan), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Secondary Iron Overload and the Liver: A Comprehensive Review.Journal of clinical and translational hepatology · 2023
    Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shinjiro InomataDepartment of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan.
Akira AnanDepartment of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan.
Eri YamauchiDepartment of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan.
Ryo YamauchiDepartment of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan.
Hideo KunimotoDepartment of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan.
Kazuhide TakataDepartment of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan.
Takashi TanakaDepartment of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan.
Keiji YokoyamaDepartment of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan.
Daisuke MoriharaDepartment of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan.
Yasuaki TakeyamaDepartment of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan.
Makoto IrieDepartment of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan.
Satoshi ShakadoDepartment of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan.
Tetsuro SohdaDepartment of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan.
Shotaro SakisakaDepartment of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective Hepcidin is a master iron regulator hormone produced by the liver, but precise mechanism underlying its involvement in iron overload in hepatitis C virus (HCV) infection remains unclear. We investigated the serum hepcidin levels against iron overload before and after HCV eradication. Methods We prospectively investigated the iron metabolism characteristics in 24 patients with HCV genotype 1b infection before and after treatment. We also assessed the serum erythroferrone (ERFE) levels to investigate its association with iron metabolism changes. Patients were treated with Ledipasvir 90 mg and Sofosbuvir 400 mg once daily for 12 weeks and observed for 12 more weeks in order to evaluate their sustained virological response. Results Serum hepcidin levels at baseline were in the normal range, although serum ferritin levels were increased. After HCV eradication, both serum ferritin and hepcidin levels were significantly decreased at 24 weeks from baseline (p<0.001, p=0.006, respectively). However, the serum hepcidin-to-ferritin ratios were significantly increased (p<0.001). In addition, the serum ERFE levels were significantly decreased (p<0.001). Increases in the serum hepcidin-to-ferritin ratios were correlated with decreases in the serum ERFE levels (ρ=-0.422, p=0.039). Conclusion Serum hepcidin levels were relatively low against ferritin levels in HCV infection. However, after HCV eradication, the serum hepcidin-to-ferritin ratios were increased. These results indicate the improvement of inadequate hepcidin secretion against iron overload after HCV eradication. Downregulation of ERFE may have affected the improvement of iron metabolism.

Indexed as

AdultAgedAntiviral AgentsBenzimidazolesFemaleFerritinsFluorenesHepacivirusHepatitis C, ChronicHepcidinsHumansIronIron OverloadMaleMiddle AgedPeptide HormonesAntiviral AgentsBenzimidazolesErfe protein, humanFerritinsFluorenesHAMP protein, humanHepcidinsIronledipasvir, sofosbuvir drug combinationPeptide HormonesSofosbuvirUridine Monophosphatedirect-acting antiviral agentserythroferroneferritinhepatitis C virushepcidin

Identifiers

PMID31243222
PMCPMC6859405

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.